Patents Assigned to Wyeth
  • G protein-binding proteins and polynucleotides encoding the same
    Publication number: 20050214830
    Abstract: Novel proteins which contain a structural module conserved in the G protein coupled receptor superfamily, polynucleotides which encode these proteins, and methods for producing these proteins are provided. Diagnostic, therapeutic, and screening methods employing the polynucleotides and polypeptides of the present invention are also provided.
    Type: Application
    Filed: February 7, 2005
    Publication date: September 29, 2005
    Applicant: Wyeth
    Inventors: Bradley Ozenberger, Eileen Kajkowski, Ching-Hsiung Frederick Lo, Heidi Sofia
  • 7-aryl 1,5-dihydro-4, 1-benzoxazepin-2(3H)-one derivatives and their use as progesterone receptor modulators
    Publication number: 20050215539
    Abstract: This invention provides progesterone receptor modulators having the structure: wherein R1 to R7, X, and Q are as defined in the specification; or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: March 22, 2005
    Publication date: September 29, 2005
    Applicant: Wyeth
    Inventors: Puwen Zhang, Jay Wrobel, Eugene Terefenko, Jeffrey Kern
  • 2-Phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents
    Publication number: 20050215616
    Abstract: The present invention relates to new 2-Phenyl-1-[4-(2-Aminoethoxy)-Benzyl]-Indole compounds having the general structures below: which are useful in treating vaginal and skin atrophy.
    Type: Application
    Filed: May 19, 2005
    Publication date: September 29, 2005
    Applicant: Wyeth
    Inventors: Chris Miller, Michael Collini, Bach Tran, Arthur Santilli
  • Processes for the preparation of iodinated amino-aryl compounds
    Publication number: 20050215812
    Abstract: The present invention provides processes for the preparation of amino-aryl iodides wherein a micronized amino-aryl compound is reacted with an iodinating reagent.
    Type: Application
    Filed: March 24, 2005
    Publication date: September 29, 2005
    Applicant: Wyeth
    Inventor: Ronald Michalak
  • 3-substituted-3-(substitutedsulfonyl or sulfanyl) pyrrolidine-2,5-diones useful for inhibition of farnesyl-protein transferase
    Patent number: 6949661
    Abstract: The invention relates to compounds of Formula (I), to processes for their preparation and pharmaceutical compositions thereof, that inhibit the Ras farnesyl-protein transferase enzyme (FPTase), and may be used as an alternative to, or in conjunction with, traditional cancer therapy for the treatment of ras oncogene-dependent tumors, such as cancers of the pancreas, colon, bladder, and thyroid.
    Type: Grant
    Filed: September 26, 2003
    Date of Patent: September 27, 2005
    Assignee: Wyeth Holdings Corporation
    Inventors: Joseph William Epstein, Semiramis Ayral-Kaloustian
  • Method for excystation of sporocysts
    Patent number: 6949375
    Abstract: A process to excystate protozoal sporocysts involves treatment of an infected tissue sample with a sodium hypochlorite solution to stimulate excystation of the sporocysts from the tissue. Thereafter, removal of the sodium hypochlorite solution and treatment of the sample with a cell culture media as the excystation fluid eliminates incubation and subsequent washing steps using expensive reagents. The excystation fluid contains substantially no chelating agents, proteins, enzymes or bile acids.
    Type: Grant
    Filed: October 15, 2002
    Date of Patent: September 27, 2005
    Assignee: Wyeth
    Inventors: Neil J. Jennings, Kirsten I. Dinka
  • Compounds which inhibit leukocyte adhesion mediated by VLA-4
    Patent number: 6949570
    Abstract: Disclosed are compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.
    Type: Grant
    Filed: May 7, 2002
    Date of Patent: September 27, 2005
    Assignees: Elan Pharmaceuticals, Inc., Wyeth
    Inventors: Susan Ashwell, Reinhardt Bernhard Baudy, Michael A. Pleiss, Dimitrios Sarantakis, Eugene D. Thorsett
  • Process for preparing N-aryl-piperazine derivatives
    Publication number: 20050209245
    Abstract: Processes for preparing N-aryl-piperazine derivatives of formula I particularly (R)-4-cyano-N-[2-[4-(2,3-dihydro-1,4-benzodioxan-5-yl)-1-piperazinyl-propyl]-N-(2-pyridinyl)-benzamide, are disclosed. Compositions comprising N-aryl-piperazine derivatives and low levels of common impurities are also disclosed. In addition, products produced by the process are disclosed.
    Type: Application
    Filed: March 17, 2005
    Publication date: September 22, 2005
    Applicant: Wyeth
    Inventors: Anita Chan, Jianxin Ren, Archana Sharma
  • Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors
    Patent number: 6946473
    Abstract: Compounds of the formula which are useful in disease conditions mediated by TNF-?, such as rheumatoid arthritis, osteoarthritis, sepsis, AIDS, ulcerative colitis, multiple sclerosis, Crohn's disease and degenerative cartilage loss.
    Type: Grant
    Filed: March 17, 2003
    Date of Patent: September 20, 2005
    Assignee: Wyeth Holdings Corporation
    Inventors: Jeremy I. Levin, James M. Chen, Xue-Mei Du, Jay D. Albright, Arie Zask
  • Thio-oxindole derivatives
    Patent number: 6946454
    Abstract: This invention relates to methods of co-administering compounds of formula 1 which are agonists of the progesterone receptor which have the general structure: wherein: R1, R2, R3, R4, R5 and Q1 are as defined herein, or a pharmaceutically acceptable salt thereof, with estrogen, an estrogen, or an estrogen receptor agonist for contraception, hormone replacement therapy, or treating progesterone-related carcinomas and adenocarcinomas.
    Type: Grant
    Filed: April 5, 2002
    Date of Patent: September 20, 2005
    Assignees: Wyeth, Ligand Pharmaceuticals, Inc.
    Inventors: Andrew Fensome, Puwen Zhang, Marci C. Koko, Lin Zhi, Todd K. Jones, Jay E. Wrobel, Christopher M. Tegley, James P. Edwards, Edward G. Melenski
  • Canine vaccine for protection against ehrlichiosis
    Publication number: 20050202046
    Abstract: The present invention provides a safe and effective vaccine composition which comprises: an effective immunizing amount of an inactivated Ehrlichia canis bacterin; a pharmacologically acceptable carrier; and an immunogenically stimulating amount of an adjuvant system consisting essentially of an antibody response inducing agent and a cell-mediated immunity response inducing agent. The present invention also provides a method for the prevention or amelioration of canine ehrlichiosis in dogs.
    Type: Application
    Filed: March 9, 2005
    Publication date: September 15, 2005
    Applicant: Wyeth
    Inventors: Liangbiao (George) Hu, Thomas Hess, Yu-Wei Chiang, Hsien-Jue (Steve) Chu
  • Functional method for generating or screening for ligands which modulate steroid hormone receptors
    Publication number: 20050202515
    Abstract: This application presents the discovery that the Vitamin D3 receptor (VDR), a member of the nuclear hormone ligand-activated receptor superfamily, interacts with a MNAR, a scaffolding protein. This interaction results in the formation of a ternary complex between VDR, MNAR, and the Src or PI3 kinase families of tyrosine kinases to mediate cell signaling, especially in osteoblast cells.
    Type: Application
    Filed: February 25, 2005
    Publication date: September 15, 2005
    Applicant: Wyeth
    Inventors: Frank Barletta, Greg O'Donnell, Boris Cheskis
  • Hydantoins having RNase modulatory activity
    Publication number: 20050203156
    Abstract: The present invention relates to hydantoin derivatives having RNase H, polymerase and/or HIV reverse transcriptase modulatory, and particularly, inhibitory activity. Included in the invention are the hydantoin derivatives, compositions containing the derivatives, methods of synthesis of the derivatives, screening methods to identify the derivatives, and methods of treatment using the hydantoin derivatives, including the treatment of HIV, AIDS and retrovirus-associated cancer.
    Type: Application
    Filed: March 11, 2005
    Publication date: September 15, 2005
    Applicant: Wyeth
    Inventors: Matthew Olson, Martin Grandi, Amarnauth Prashad
  • Carbamates as HIV anti-viral agents
    Publication number: 20050203176
    Abstract: The present invention relates to carbamate derivatives having RNase H, polymerase and/or HIV reverse transcriptase modulatory, and particularly, inhibitory activity. Included in the invention are the carbamate derivatives, compositions containing the derivatives, methods of synthesis of the derivatives, screening methods to identify the derivatives, and methods of treatment using the carbamate derivatives, including the treatment of HIV, AIDS and retrovirus-associated cancer.
    Type: Application
    Filed: March 11, 2005
    Publication date: September 15, 2005
    Applicant: WYETH
    Inventors: Matthew Olson, Martin Grandi, Amarnauth Prashad
  • Serotonergic agents with long-acting in vivo effects
    Publication number: 20050202412
    Abstract: Compounds of the formula have a long duration of action and are useful for the treatment of chronic diseases resulting from the dysfunction of the serotonergic 5-HT1A system, such as schizophrenia and other psychotic disorders such as paranoia and mano-depressive illness.
    Type: Application
    Filed: April 12, 2005
    Publication date: September 15, 2005
    Applicant: Wyeth
    Inventors: Wayne Childers, Michael Kelly, Lee Schechter, Sharon Rosenzweig-Lipson
  • Removal of bacterial endotoxin in a protein solution by immobilized metal affinity chromatography
    Patent number: 6942802
    Abstract: The present invention relates to the purification of polypeptides and the removal of endotoxin via immobilized metal affinity chromatography (IMAC). More specifically, the invention relates to methods for removing bacterial endotoxin in a protein solution. In specific embodiments, the invention relates to the elimination of endotoxin from Moraxella catarrhalis outer membrane proteins.
    Type: Grant
    Filed: April 5, 2002
    Date of Patent: September 13, 2005
    Assignee: Wyeth Holdings Corporation
    Inventors: Rhonda Lunt Sundberg, Robert Leonard Hopfer
  • Antidepressant azaheterocyclylmethyl derivatives of 1,4,5-trioxa-phenanthrene
    Patent number: 6943178
    Abstract: Compounds of the formula useful for the treatment of diseases such as depression (including but not limited to major depressive disorder, childhood depression and dysthymia), anxiety, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder attention deficit disorder (with and without hyperactivity), obsessive compulsive disorder (including trichotillomania), social anxiety disorder, generalized anxiety disorder, obesity, eating disorders such as anorexia nervosa, bulimia nervosa, vasomotor flushing, cocaine and alcohol addiction, sexual dysfunction and related illnesses.
    Type: Grant
    Filed: June 30, 2004
    Date of Patent: September 13, 2005
    Assignee: Wyeth
    Inventors: Megan Tran, Gary P. Stack
  • Antiparasitic composition
    Publication number: 20050197302
    Abstract: There is provided an improved antiparasitic composition comprising an antiparasitically effective amount of an organic amine salt of closantel optionally a macrocyclic lactone and a non-irritating solvent system consisting essentially of an alcohol and a glycol derivative. Also provided are a method for obtaining increased levels of closantel in the blood of a homeothermic animal and a method for the enhanced protection of said animal from parasitic infection.
    Type: Application
    Filed: January 14, 2005
    Publication date: September 8, 2005
    Applicant: Wyeth
    Inventor: Robert Albright
  • Heterocyclic sulfonamide inhibitors of beta amyloid production
    Publication number: 20050196813
    Abstract: Compounds of Formula (I), wherein R1, R2, R3, R4, R5, R6, T, W, X, Y and Z are as defined herein are provided, together with pharmaceutically acceptable salt, hydrates and/or prodrugs thereof.
    Type: Application
    Filed: March 16, 2005
    Publication date: September 8, 2005
    Applicant: Wyeth
    Inventors: Anthony Kreft, Derek Cole, Kevin Woller, Joseph Stock, George Diamantidis, Dennis Kubrak, Kristina Kutterer, William Moore, David Casebier
  • Non-immunosuppressive immunophilin ligands as neuroprotective and/or neuroregenerative agents
    Publication number: 20050197356
    Abstract: This invention relates, in part, to the use of non-immunosuppressive immunophilin ligands, such as meridamycin, in treating neurological disorders.
    Type: Application
    Filed: February 25, 2005
    Publication date: September 8, 2005
    Applicant: Wyeth
    Inventors: Edmund Graziani, Kevin Pong